United States 119th Congress Status: In Committee Bipartisan · sponsors 28 D · 7 R

HR 10770 — 340B Rebate Model Delay Act

Last action — Referred to the House Committee on Energy and Commerce.

Write to your legislator about it: a free email template →

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced October 09, 2026. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

In plain language

This bill aims to temporarily limit rebate use in the 340B Program.

The 340B Rebate Model Delay Act seeks to amend the Public Health Service Act to restrict rebates under the 340B Program for a limited time. The exact details of the limitations are not available as the bill text is not provided.

Summary

To amend title III of the Public Health Service Act to temporarily limit the use of rebates under the 340B Program.

Bill Text

Sections of law this bill changes

1 section in 1 law

From the bill's own amending language, matched to the official United States Code (current through Public Law 119-142).

Public health service · 42 U.S.C. ch. 6A 1 section
  • § 256b Limitation on prices of drugs purchased by covered entities Amends

    42 U.S.C. § 256b — at 256b(a)

    The law today

    (a) Requirements for agreement with Secretary (1) In general The Secretary shall enter into an agreement with each manufacturer of covered outpatient drugs under which the amount required to be paid (taking into account any rebate or discount, as provided by the Secretary) to the manufacturer for covered outpatient drugs (other than drugs described in paragraph (3)) purchased by a covered entity on or after the first day of the first month that begins after November 4, 1992, does not exceed an amount equal to the average manufacturer price for the drug under title XIX of the Social Security Act [42 U.S.C. 1396 et seq.] in the preceding calendar quarter, reduced by the rebate percentage described in paragraph (2). Each such agreement shall require that the manufacturer furnish the Secretary with reports, on a quarterly basis, of the price for each covered outpatient drug subject to the agreement that, according to the manufacturer, represents the maximum price that covered entities may permissibly be required to pay for the drug (referred to in this section as the “ceiling price”), and shall require that the manufacturer offer each covered entity covered outpatient drugs for purchase at or below the applicable ceiling price if such drug is made available to any other purchaser at any price. (2) “Rebate percentage” defined (A) In general For a covered outpatient drug purchased in a calendar quarter, the “rebate percentage” is the amount (expressed as a percentage) equal to— (i) the average total rebate required under section 1927(c) of the Social Security Act [42 U.S.C. 1396r–8(c)] with respect to the drug (for a unit of the dosage form and strength involved) during the preceding calendar quarter; divided by (ii) the average manufacturer price for such a unit of the drug during such quarter. (B) Over the counter drugs (i) In general For purposes of subparagraph (A), in the case of over the counter drugs, the “rebate percentage” shall be determined as if the rebate required under section 1927(c) of the Social Security Act [42 U.S.C. 1396r–8(c)] is based on the applicable percentage provided under section 1927(c)(3) of such Act. (ii) “Over the counter drug” defined The term “over the counter drug” means a drug that may be sold without a prescription and which is prescribed by a physician (or other persons authorized to prescribe such drug under State law). (3) Drugs provided under State medicaid plans Drugs described in this paragraph are drugs purchased by the entity for which payment is made by the State under the State plan for medical assistance under title XIX of the Social Security Act [42 U.S.C. 1396 et seq.]. (4) “Covered entity” defined In this section, the term “covered entity” means an entity that meets the requirements described in paragraph (5) and is one of the following: (A) A Federally-qualified health center (as defined in section 1905(l)(2)(B) of the Social Security Act [42 U.S.C. 1396d(l)(2)(B)]). (B) An entity receiving a grant under section 256a 1 of this title. (C) A family planning project receiving a grant or contract under section 300 of this title. (D) An entity receiving a grant under subpart II 1 of part C of subchapter XXIV (relating to categorical grants for outpatient early intervention services for HIV disease). (E) A State-operated AIDS drug purchasing assistance program receiving financial assistance under subchapter XXIV. (F) A black lung clinic receiving funds under section 937(a) of title 30. (G) A comprehensive hemophilia diagnostic treatment center receiving a grant under section 501(a)(2) of the Social Security Act [42 U.S.C. 701(a)(2)]. (H) A Native Hawaiian Health Center receiving funds under the Native Hawaiian Health Care Act of 1988. (I) An urban Indian organization receiving funds under title V of the Indian Health Care Improvement Act [25 U.S.C. 1651 et seq.]. (J) Any entity receiving assistance under subchapter XXIV (other than a State or unit of local government or an entity desc...

    67 other bills also change this section · Follow it → Official text at uscode.house.gov ↗

How this bill changes current law

2 changes Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill temporarily limits the use of rebates under the 340B Program by prohibiting agreements that allow payments to exceed ceiling prices for covered outpatient drugs during a specified period.

  • 42 U.S.C. 256b(a)

    (11) Temporary limit on use of rebates.--For the period beginning on January 1, 2027, the date of enactment of this paragraph, and ending on December 31, 2028, the Secretary may not enter into an agreement with a manufacturer of covered outpatient drugs under paragraph (1) under which the amount required to be paid to the manufacturer for covered outpatient drugs by a covered entity (other than a covered entity described in paragraph (4)(E)) exceeds, at the point of purchase of such drug, the applicable ceiling price for such drug (as described in paragraph (1)).

    This addition establishes a temporary prohibition on agreements that allow payments for covered outpatient drugs to exceed their ceiling prices for a two-year period.

  • For the period beginning on January 1, 2027, the date of enactment of this section, and ending on December 31, 2028, the Secretary of Health and Human Services may not implement the 340B Rebate Model Pilot Program described in the notice titled ``Notice Regarding 340B Rebate Model Pilot Program'' (91 Fed. Reg. 48883 (August 3, 2026)), or any substantially similar program.

    This provision delays the implementation of the 340B Rebate Model Pilot Program and any similar program for the same two-year period.

Action History

  1. Referred to the House Committee on Energy and Commerce.

  2. Introduced in House

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 34 co-sponsors · 505 not signed on

Sponsors (1)

Co-sponsors (34)

Not signed on (505)

505 members have not signed on to this bill.

Show all 505 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Committees

Lobbying on this bill

From the reports lobbyists file with Congress. A report shows the bill was lobbied, not that anyone met a member about it.

1 lobbying report for 1 client names HR 10770, the latest filed October 21, 2026.

Counted from reports filed October 9, 2026 through December 16, 2028: a report names a bill by its number, not its Congress, so we count those filed within about two years of when this bill began.

See who's lobbying on HR 10770

The clients and their firms, what they reported spending, the issues and the agencies and chambers they lobbied, and former officials among the lobbyists, on any paid plan.

See plans

Source: U.S. Senate Office of Public Records, LDA.gov, retrieved October 26, 2026. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.

Subjects

Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HR 10770 do?
To amend title III of the Public Health Service Act to temporarily limit the use of rebates under the 340B Program.
Who sponsors HR 10770?
HR 10770 is sponsored by Debbie Dingell (Democratic), Tracey Mann (Republican), Lois Frankel (Democratic), Ritchie Torres (Democratic), Michael Lawler (Republican), Donald G. Davis (Democratic), Yvette D. Clarke (Democratic), Austin Scott (Republican), John W. Mannion (Democratic), Everton Blair Jr. (Democratic), Jonathan L. Jackson (Democratic), Eric Sorensen (Democratic), Jason Crow (Democratic), Chuck Edwards (Republican), Maggie Goodlander (Democratic), Suzan K. DelBene (Democratic), Stephen F. Lynch (Democratic), Lori Trahan (Democratic), Maxine Dexter (Democratic), Valerie P. Foushee (Democratic), Josh Riley (Democratic), Andrew R. Garbarino (Republican), Gabe Vasquez (Democratic), Jared F. Golden (Democratic), Gwen Moore (Democratic), Steve Cohen (Democratic), Adam Smith (Democratic), Raul Ruiz (Democratic), Troy A. Carter (Democratic), Ro Khanna (Democratic), Rick Larsen (Democratic), Gregory W. Meeks (Democratic), Mike Ezell (Republican), Darren Soto (Democratic), and Robert Bresnahan (R).
What is the current status of HR 10770?
This bill is in committee in the House. Introduced October 09, 2026. It must pass committee before a floor vote.
Where can I track HR 10770?
Track HR 10770 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 10770

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Stay ahead of HR 10770

Last checked for changes 9 days ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →